"10.1371_journal.pone.0075581","plos one","2013-09-20T00:00:00Z","Thomas Gobbetti; Pauline Le Faouder; Justine Bertrand; Marc Dubourdeau; Elisabetta Barocelli; Nicolas Cenac; Nathalie Vergnolle","Inserm, U1043, Toulouse, France; CNRS, U5282, Toulouse, France; Université de Toulouse, UPS, Centre de Physiopathologie de Toulouse Purpan (CPTP), Toulouse, France; William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London, Charterhouse Square, London, United Kingdom; Lipidomic Core Facility, Metatoul Platform, Université Paul Sabatier, Toulouse, France; Ambiotis-SAS, Canal Biotech 2, Toulouse, France; Department of Pharmacy, University of Parma, Parma, Italy","Conceived and designed the experiments: TG NV EB. Performed the experiments: TG PLF NC. Analyzed the data: TG NC JB. Contributed reagents/materials/analysis tools: MD JB. Wrote the paper: TG NV.","Dr. Marc Dubourdeau is affiliated to a commercial company, Ambiotis-SAS. This company is a contract research organization, which had only participated here to define the protocol conditions of PUFA dosing. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and material.","2013","09","Thomas Gobbetti","TG",7,TRUE,3,3,3,2,TRUE,TRUE,FALSE,0,NA,FALSE
